Asthma has traditionally been seen as a treatment-responsive and reversible inflammatory process, while COPD has been characterised by fixed airway narrowing and alveolar destruction not responsive to treatment. However, in the past two decades there has been increasing evidence on the airway non-reversibility of asthma especially among the elderly patients. This condition has been referred to as overlap syndrome, as they have overlapping features of asthma and COPD. Our case study illustrates the fact that daily high inhaled corticosteroids are the mainstay of treatment, and co-management of such patients with our respiratory colleagues is crucial in stabilising this disease.
INTRODUCTION
Asthma has been traditionally recognised as an allergic disease that develops in childhood, characterised physiologically by reversible airflow obstruction, and has an episodic course with a generally favorable prognosis, responding well to anti-inflammatory treatment 1, 2 . This is in contrast to chronic obstructive pulmonary disease (COPD) which has fixed airway narrowing and alveolar destruction poorly responding to antiinflammatory treatment. However, in the past two decades there has been increasing evidence on the airway non reversibility of asthma especially among the elderly patients. This condition has been referred to as overlap syndrome because of overlapping features of asthma and COPD in these patients. The management of these patients is made even more complicated by their concomitant medical problems, which can confuse the initial diagnosis and complicate subsequent treatment. These patients are also typically excluded from current therapy trials on asthma and COPD 2 . This aspect of asthma is not well discussed in the mainstream medical textbooks and the current Singapore clinical practice guidelines on asthma have not given guidance on management of this unique group of asthma patients 3 . Although 5-10% of asthmatics are classified to have severe asthma, the percentage among them with non-reversible airflow obstruction is currently unknown 4 . It is important for the family physician to be aware of this increasingly recognised and prevalent form of asthma locally and worldwide.
We present a case study to illustrate the complexities of diagnosis and management in this unique group of asthma patients, followed by a discussion on overlap syndrome and its similarities and differences from asthma and COPD.
CASE REPORT
Mr. LS is a 73-year-old single, unemployed Chinese man with a past medical history of ischaemic heart disease, cerebrovascular accident with right external capsule and putamen infarct and dementia. He presented with adult onset asthma in his forties and had frequent asthma exacerbations presenting to the emergency department and general practitioners. His uncontrolled asthma is due to non-adherence of medical treatment Proceedings of Singapore Healthcare  Volume 23  Number 2  2014 and non-attendance to his specialist outpatient appointments with his respiratory physicians, resulting in recurrent admissions to the hospital. During the inpatient stay he was treated with daily inhaled corticosteroids and salbutamol inhalers on an as-required basis.
Mr. LS presented to the Singapore General Hospital emergency department on October 2012 with cough and shortness of breath, with bilateral diffuse rhonchi and occasional basal crepitations, and was initially diagnosed with an acute exacerbation of asthma. He had no signs of congestive cardiac failure and the rest of his physical examination was unremarkable. His medical management was subsequently taken over by the Department of Family Medicine and Continuing Care inpatient medical team due to his recurrent admissions to the hospital.
Nebulised salbutamol and normal saline was administered and he was started on prednisolone. Although his chest radiograph showed cardiomegaly with increased vascular congestion, the consulting cardiologist's clinical impression was that the main reason for the patient breathlessness was poorly controlled asthma.
A high resolution computer tomography (HRCT) of the chest showed non-specific airway thickening in both lungs. Aspirin was stopped and changed to Plavix in view of his severe asthma.
Serial peak flow monitoring, showed no pre-or postbronchodilator response. No spirometry readings were done during this admission. Nonetheless, based on the clinical history and physical findings, two senior respiratory physicians diagnosed the patient to have non-reversible asthma, which is part of the overlap syndrome.
He was treated with salbutamol inhaler three times per day as required and 250 μg fluticasone propionate and 25 μg salmeterol Evohaler two puffs twice daily and suggested to be on long-term oxygen therapy of 1 L/min per day. Asthma action plans and inhaler techniques were taught and reinforced to both the patient and his sister. He was subsequently discharged home with appropriate caregiver training, follow-up phone calls and home visits by our integrated care nurses. He was referred for full social support services including escort services for him to attend the medical appointments. With reinforcement of strict compliance to his inhalers and follow up appointments, Mr. LS did not have any readmissions to the hospital for his asthma over a one-year follow up period.
DISCUSSION
Most of the asthma patients with overlap syndrome are elderly. Postulated risk factors include disintegrin and metalloproteinase domaincontaining protein 33 (ADAM 33) 5 expression, the sensitisation to Aspergillus fumigatus, exposure to specific occupational agents and frequent asthma exacerbations 6 .
A significant proportion of asthma patients demonstrate an incomplete reversibility of airway obstruction despite optimal treatment and absence of a significant smoking history or occupational exposure to suggest an alternative diagnosis of COPD. The irreversible component may be due to structural changes and residual airway inflammation, particularly of the eosinophilic type. The risks factors for developing incomplete reversibility of airway obstruction include reduced pulmonary function early in life, frequent exacerbations, smoking, continuing exposure to a sensitising agent, and adult onset asthma. Optimal treatment includes prevention of asthma exacerbations, smoking avoidance, and sufficient anti-inflammatory therapy 7 .
Thus, the irreversibility of the asthma in our patient may have been aggravated by his nonadherence to medical treatment and follow up medical appointments with his respiratory and family physicians.
At present there is no data, randomised trial or guidelines to help guide therapeutic interventions in overlap syndrome. Practical treatment principles are similar to those for asthma or COPD and involve a comprehensive therapy directed toward airway inflammation, airflow obstruction, and airway hyper-responsiveness. ( Table 1 and Table 2 ).
It is also important to note that many of the elderly asthmatics have concomitant co-morbidities such as congestive heart failure, which can mimic asthma. These conditions should be excluded before attributing the non-reversibility of airway obstruction to asthma.
Asthma Without Reversible Airflow Obstruction
Proceedings of Singapore Healthcare  Volume 23  Number 2  2014
In patients with overlap syndrome, high dose inhaled corticosteroids may be of benefit. Benefit may be seen in some cases with leukotriene modifiers, especially in the large percentage (20-25%) of patients with severe asthma who may have aspirin sensitive asthma). Long-acting β-agonists along with inhaled corticosteroids are also of benefit for patients with severe asthma 9 .
A limitation of this case study is that no spirometry readings were done for this patient pre-and postbronchodilators for the reasons as discussed earlier. The likely spirometry readings would have been FEV1/FVC <70% with FEV1% predicted at <80% ( Table 2) .
Learning points
1. Traditionally, asthma has been taught as an atopic disease with airway reversibility. However in the group of elderly patients, this is not necessarily the case. Non-reversible asthma is currently under recognised.
2. These patients also do not fulfill the clinical criteria for COPD.
3. Instead they have features of both asthma and COPD, known as overlap syndrome.
4. The prevalence is increasing and these patients are rarely recruited for current therapy trials for asthma. 
A sizeable proportion of these patients have

Inhaled bronchodilators
Inhaled short-acting β2-agonists are the mainstay of treatment for intermittent asthma Inhaled long-acting β2-agonists monotherapy is not recommended
The mainstay of treatment in patients with COPD; inhaled anticholinergics may be more effective than inhaled β2-agonists as monotherapy in COPD No data available FEV1, forced expiratory volume in 1s; ICS, inhaled corticosteroid. 
